Wilmington, Delaware, United States, Transparency Market Research Inc. – The global non-alcoholic steatohepatitis biomarkers market was valued at ~US$ 300 Mn in 2018 and is projected to expand at a rapid pace from 2019 to 2027.
Wilmington, Delaware, United States, Transparency Market Research Inc. – The global non-alcoholic steatohepatitis (NASH) biomarkers market was valued at ~US$ 300 Mn in 2018 and is projected to expand at a rapid pace from 2019 to 2027. Rise in NAFLD and NASH conditions; increase in patient pool suffering from obesity and metabolic diseases; rise in geriatric population; growth in Type 2 diabetes and pre-diabetes in adult patients; surge in demand for non-invasive diagnostic techniques; and increase in awareness about NASH condition and innovative diagnosis tools, especially in developing markets, are anticipated to propel the global non-alcoholic steatohepatitis biomarkers market.
NASH, also known as non-alcoholic steatohepatitis, is a progressive form of non alcoholic fatty liver disease (NAFLD). NAFLD is a condition in which fat is accumulated in the liver and the continuous fat deposition may cause liver inflammation and liver cell damage. This is termed as NASH condition. Increase in worldwide prevalence of obesity, type 2 diabetes, pre-diabetes, and metabolic diseases are major reasons for increase in prevalence of non-alcoholic steatohepatitis condition. Thus, innovative diagnostic tools are introduced in the market to accurately diagnose the non-alcoholic steatohepatitis condition.
Request Sample of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=18650
Liver biopsy is one of the standard tools for diagnosis of NASH condition. However, due to high cost of this procedure, many companies have introduced biomarkers as a diagnostic tool for NASH patients. Various non-invasive biomarkers are available for detection of the NASH condition, including serum biomarkers, biomarker panels, fibrosis biomarkers, imaging biomarkers, gene biomarkers, oxidative stress biomarkers, and Cytokeratin-18.
As per research, worldwide prevalence of NASH is estimated to be in a range of 1.5%–6.45%, respectively, in 2019. NASH prevalence across globe is expected to grow by 63% by 2030. Several pharmaceutical and biotechnology companies are investing in development of therapeutics for NASH. Currently, 95 drug candidates from different players are in pipeline ranging from preclinical to phase 3 trials. These players would require NASH biomarker diagnostics to monitor and evaluate drug effectiveness during clinical trials. Various companies have entered into collaboration to further strengthen and develop biomarkers, thereby augmenting the NASH biomarkers market in the near future.
Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=18650
Non-alcoholic Steatohepatitis (NASH) Biomarkers Market: Segmentation
The global non-alcoholic steatohepatitis (NASH) biomarkers market has been segmented based on biomarker type, end user, and region
In terms of biomarker, the global non-alcoholic steatohepatitis (NASH) biomarkers market has been classified into serum biomarkers, biomarker panels, fibrosis biomarkers, imaging biomarkers, and others. The serum biomarkers segment is further classified into cytokeratin-18 (CK 18) marker, inflammatory markers, and others. The serum biomarkers segment held a largest market share, owing to availability of various tests in the market. The segment also has higher accuracy in differentiating NASH indications.
Cell apoptosis increases during the progression of NASH. Markers such as fragments of cytokeratin-18 and ferritin are measured and found to be promising markers of NASH. CK-18 is considered as the popular and potential biomarker for detecting NASH indication. The others segment includes gene biomarkers and oxidative stress biomarkers which offer promising results in terms of higher accuracy and are considered to be inexpensive and simple non-invasive techniques.
In terms of end user, the global non-alcoholic steatohepatitis (NASH) biomarkers market has been segregated into hospitals, diagnostic centers, and others. The diagnostic centers segment dominated the global non-alcoholic steatohepatitis (NASH) biomarkers market in 2018, owing to increase in awareness about the NASH indication for early diagnosis followed by its effective treatment. Availability of technically advanced tools such as biomarkers tests in diagnostic centers coupled with presence of expertise is likely to drive the diagnostic centers segment.
Ask for References - https://www.transparencymarketresearch.com/sample/sample.php?flag=ARF&rep_id=18650
Non-alcoholic Steatohepatitis (NASH) Biomarkers Market: Regional Segmentation
In terms of region, the global non-alcoholic steatohepatitis (NASH) biomarkers market has been split into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
North America dominated the global non-alcoholic steatohepatitis (NASH) biomarkers market in 2018, owing to rise in prevalence of NASH associated conditions such as obesity and type 2 diabetes in the region. Several market players such as Quest Diagnostics for Hepascore and Exalenz Biosciences Ltd. are opting to enter North America through collaborations and alliances.
Demand for non-invasive diagnostic tests for NASH and related diseases is high due to accuracy and operational limitations and associated hazards of liver biopsy. Rise in adoption of minimal invasive surgeries, growing geriatric population, and investments by key players in R&D to develop innovative and promising biomarkers are estimated to boost the non-alcoholic steatohepatitis (NASH) biomarkers market in the region.
The non-alcoholic steatohepatitis (NASH) biomarkers market in Latin America and Middle East & Africa is anticipated to expand at a faster pace than other regions during the forecast period. Rising patient population suffering from NASH condition is a major factor likely to propel the market in Latin America and the Middle East. Latin America likely to exhibit highest CAGR, owing to prevalence of NASH condition. For instance, in Brazil, the prevalence rate of NASH condition is 35.2%, in Chile, it is 23%, in Mexico, it is around 17%, and in Columbia it is around 26.6%. As per NCBI, the prevalence of NASH indication in Middle East & Africa is estimated to reach more than 12,534,000 cases in Saudi Arabia and 372,000 cases in the UAE by 2030. All these statistics are likely to boost the NASH biomarkers market in the region.
Make an Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=18650
Non-alcoholic Steatohepatitis (NASH) Biomarkers Market: Major Players
Key players operating in the global non-alcoholic steatohepatitis (NASH) biomarkers market include
- Biopredictive
- Quest Diagnostics
- Exalenz Bioscience Ltd
- GENFIT
- Siemens Healthineers
- ONE WAY LIVER
- S.L
- Prometheus Laboratories Inc
- Gilead Sciences Ltd.
These players are focused on adopting organic and inorganic growth strategies to strengthen product portfolio and expand their alliances with other companies. Key players have adopted strategies such as investment into research & development of efficient non-invasive biomarkers, creating awareness about non-alcoholic steatohepatitis indication, expansion of geographic footprint, and collaborations & acquisitions, in order to be competitive in the global non-alcoholic steatohepatitis (NASH) biomarkers market.
More Trending Reports by Transparency Market Research –
Dry Eye Disease Diagnostics & Treatment Market: The global dry eye disease diagnostics & treatment market is on the course to reach US$ 9.8 Bn by the end of 2030.
Topical Antibiotics Market: The global topical antibiotics market is anticipated to attain a market value of US$ 8.3 Bn by the end of 2030.
In-vitro Inflammatory Bowel Disease Diagnostic Market: The global in-vitro inflammatory bowel disease diagnostics market is expected to expand at a CAGR of ~4% during the forecast period.
Depression Drugs Market: The global depression drugs market is expected to attain a market value of US$ 24.3 Bn by the end of 2030.
Dry Eye Disease Treatment Market: The global dry eye disease treatment market was valued at US$ 5.4 Bn in 2019 and is anticipated to expand at a CAGR of ~4% from 2020 to 2030.
Alcoholic Hepatitis Therapeutics Market: The global alcoholic hepatitis therapeutics market is expected to reach ~US$ 1.2 Bn by the end of 2030.
Atipamezole Market: The global atipamezole market for the historical period 2018–2019 and forecast period 2020–20230, increase in healthcare expenditure on animals boosts the global atipamezole market.
Anticoagulant Reversal Drug Market: The anticoagulant reversal drugs market to expand at a CAGR of 15.6% during the forecast period from 2018 to 2026.
About Us
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ
Contact
Rohit Bhisey
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Blog: https://tmrblog.com
Email: sales@transparencymarketresearch.com